Early studies have shown that a high immune cytolytic activity (CYT) is significantly associated with significant pan-cancer survival benefits (Rooney et al., 2015) and effectively corresponds to anti-CTLA-4 and anti-PD-L1 immunotherapy (Ji et al., 2012; Herbst et al., 2014). This evidence concerns the gene CD274 and cancer.